Clinical and functional features of dilated cardiomyopathy in cancer patients after covid-19 infection
Keywords:
Dilated cardiomyopathy; COVID-19; cardio-oncology; heart failure; myocardial injury; long COVID; cardiotoxicity; cancer patients; inflammatory cardiomyopathy.Abstract
Background Dilated cardiomyopathy (DCM) remains one of the leading causes of chronic heart failure worldwide. The COVID-19 pandemic has significantly changed the clinical landscape of cardiovascular diseases, revealing new mechanisms of myocardial injury. Patients with cancer represent a particularly vulnerable group due to cardiotoxic anticancer therapies and immune dysfunction. The combined impact of oncological disease, cardiotoxic treatment and SARS-CoV-2 infection may lead to rapid progression of heart failure and unfavorable outcomes. Aim To analyze clinical and functional features of dilated cardiomyopathy in patients with oncological diseases after COVID-19 infection. Materials and Methods A narrative literature review and clinical case analysis were performed. Contemporary studies on post-COVID cardiovascular complications, inflammatory cardiomyopathy and cardio-oncology were analyzed. Particular attention was paid to mechanisms of myocardial injury and progression of heart failure in cancer patients after SARS-CoV-2 infection. Results Recent evidence demonstrates that SARS-CoV-2 has a pronounced tropism for cardiomyocytes and vascular endothelium via ACE2 receptors. The main mechanisms of myocardial injury include direct viral cytotoxicity, cytokine storm, endothelial dysfunction, microvascular thrombosis and autoimmune inflammation. Long-term follow-up studies show a significantly increased risk of heart failure, arrhythmias and dilated cardiomyopathy after COVID-19. Cancer patients represent a high-risk population due to cardiotoxic chemotherapy, immune checkpoint inhibitors and radiation therapy. The risk of heart failure after COVID-19 in oncology patients increases by 2–3 times, while thromboembolic complications occur several times more frequently. The presented clinical case illustrates rapid progression of heart failure and fatal outcome in a patient with DCM after COVID-19 infection, consistent with the phenotype of post-COVID inflammatory cardiomyopathy. Conclusion SARS-CoV-2 infection should be considered an independent trigger of dilated cardiomyopathy progression. Cancer patients represent an extremely high-risk group due to synergistic myocardial injury caused by cardiotoxic therapy and post-COVID inflammatory mechanisms. Early cardiovascular risk stratification and multidisciplinary management are essential to improve outcomes in this patient population.
BJMS, Vol. 25 No. 02 April’26 Page: 633-638
191
249
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Gulzada Nurgaliyeva, Irina Volchkova, Almagul Kauysheva, Sayakhat T Olzhayev, Baurzhan Zh Adjibayev, Karlygash N Tazhibayeva, Ainur M Sadykova, Raikhan Muratbekova, Mira Zhunissova, Barno T Kamelzhanova, Assel D Sadykova
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in the Bangladesh Journal of Medical Science agree to the following terms that:
- Authors retain copyright and grant Bangladesh Journal of Medical Science the right of first publication of the work.
Articles in Bangladesh Journal of Medical Science are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.- Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.
